Previous Article | Next Article ![]()
Journal of Clinical Microbiology, January 2000, p. 333-340, Vol. 38, No. 1
Department of Microbiology, Montana State University,
Bozeman, Montana 59717-3520,1 and
Department of Pathology, University of Virginia Health
System, Charlottesville, Virginia 229082
Received 22 July 1999/Returned for modification 28 September
1999/Accepted 29 October 1999
A novel microtiter assay for antifungal susceptibility testing was
developed. This method has several potential advantages over the M27-A
assay of the National Committee for Clinical Laboratory Standards.
These include provision of MIC results within 6 to 19 h, graphical
display of data, and the availability of objective quantitative
endpoints. We refer to the method as the rapid susceptibility assay
(RSA). RSA is based on substrate utilization by fungi in the presence
of antifungal drugs. Substrate uptake is determined by a colorimetric
method, which can be scored by analysis of data obtained from a
microplate reader. Variables evaluated in the development of the RSA
included inoculum size, incubation period, and efficacy with different
classes of antifungal drugs and different yeast isolates. With the
rapidly available and quantitative endpoints of the RSA, correlation of
MICs and therapeutic drug doses can be evaluated more successfully than
they can be evaluated by existing assays.
0095-1137/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Determination of Antifungal MICs by a Rapid
Susceptibility Assay
*
Corresponding author. Mailing address: Department of
Microbiology, Montana State University, Bozeman, MT 59717-3520. Phone: (406) 994-2373. Fax: (406) 994-4926. E-mail:
umbjc{at}montana.edu.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»